
---
title: '国信证券：医药板块回调趋势放缓，板块战略配置价值显现'
categories: 
    - 金融
    - 证券时报网 - 快讯
author: 证券时报网 - 快讯
comments: false
date: Mon, 22 Mar 2021 11:00:00 GMT
thumbnail: ''
---

<div>   
<p>证券时报网讯，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002736" code="002736">国信证券</a>指出，医药板块回调趋势放缓，板块战略配置价值显现。上周生物医药板块整体下跌0.83%，表现强于整体市场，医药商业、化学制药及中药子板块本周均有正收益。随着龙头股近期的持续回调，部分标的估值已趋于合理，近期年报和一季报陆续披露，龙头公司有望继续兑现高增长，进一步提振市场信心。同时也建议关注部分基本面较好、风险收益比更高的优质二线标的。推荐关注：<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300760" code="300760">迈瑞医疗</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ000739" code="000739">普洛药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600079" code="600079">人福医药</a>、远大医药、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300003" code="300003">乐普医疗</a>、中国中药、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002603" code="002603">以岭药业</a>。</p><p></p><p></p><p></p><p></p>
                  
</div>
            